This table shows the list known insiders, and is generated automatically from filings disclosed to the SEC. In addition to the names, most recent title, and director, officer, or 10% owner designation, we provide the latest disclosed holdings.
| Name | Shares | Options |
|---|---|---|
| GADICKE ANSBERT | 6,328,095 | 0 |
| EVNIN LUKE | 4,524,425 | 0 |
| UBS Oncology Impact Fund L.P. | 3,898,422 | 0 |
| MPM BioVentures 2014, L.P. | 3,220,844 | 0 |
| Chin Mark By Arix Bioscience Holdings Limited | 2,572,359 | 0 |
| New Leaf Ventures III, L.P. | 913,860 | 0 |
| HUNT RONALD | 913,860 | 0 |
| Baeuerle Patrick | 262,136 | 0 |
| Wesche Holger | 52,852 | 0 |
| Sacks Natalie | 45,754 | 0 |
| Erbez Georgia By IRA | 19,215 | 0 |
| Erbez Georgia | 8,915 | 0 |
| McMahon Gerald PhD | 3,000 | 0 |
| Colowick Alan | 0 | 0 |
| Viney Joanne L. | 0 | 0 |
| Myers Scott Dunseth | 0 | 0 |
| Chin Mark | 0 | 0 |
| BAILES JOSEPH S | 0 | 0 |
| DRACHMAN JONATHAN G | 0 | 0 |
| 0 | 0 | |
| EASTLAND JULIA MARIE | 0 | 0 |
| Robbins Andrew R | 0 | 0 |
| Arix Bioscience plc | 0 | 0 |
| MPM ASSET MANAGEMENT LLC | 0 | 0 |
While Insider sales are normal part of tax harvesting and is part of compensation of executives - A large number of transactions would indicate that the management isnt convinced that the price will go up and hence reducing their holding. This would be a possible indicator or fall in price
| Name | Shares | Price | Date |
|---|
Insider buys arent usual, since it indicates a high conviction by the management that they believe the price will go up eventually. Usually a good sign that investors should consider this as a factor to purchase a stock, especially if the current SP is lower than the price the management bought these at. The table below doesnt include any Stock Options or RSUs. They're just open market purchases by the insiders.
| Name | Shares | Price | Date |
|---|